FDA Review of Varenicline and Risk of Cardiovascular Adverse Events

Published Online: Wednesday, December 19, 2012
Follow Pharmacy_Times:
This podcast, from the Centers for Disease Control and Prevention, discusses a drug safety communication released by the FDA on December 12, 2012, regarding the risk of cardiovascular adverse events associated with the smoking-cessation drug varenicline (Chantix).
 
To download the podcast, click here.
Related Articles
Light or moderate alcohol intake has been associated with health benefits such as reduced risk of cardiovascular events, but these benefits disappear as intake increases.
While statins are among the most commonly prescribed medications for the prevention of cardiovascular disease, a recent study suggests that the use of statins may increase a patient’s risk of developing cataracts.
New worldwide estimates point to 1 billion current tobacco users, translating to 22.5% of the world’s population.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$